Arcadia Biosciences Inc (RKDA) - Total Liabilities
Based on the latest financial reports, Arcadia Biosciences Inc (RKDA) has total liabilities worth $2.41 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Arcadia Biosciences Inc - Total Liabilities Trend (2012–2025)
This chart illustrates how Arcadia Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. See Arcadia Biosciences Inc (RKDA) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Arcadia Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Arcadia Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Digital Ally Inc
NASDAQ:DGLY
|
USA | $17.56 Million |
|
AnalytixInsight Inc
V:ALY
|
Canada | CA$1.93 Million |
|
Valion Bio Inc
NASDAQ:VBIO
|
USA | $14.81 Million |
|
Freight Technologies Inc
NASDAQ:FRGT
|
USA | $5.92 Million |
|
Northcliff Citranusa Indonesia Tbk PT
JK:SKYB
|
Indonesia | Rp7.94 Billion |
|
Streamline Health Solutions Inc
NASDAQ:STRM
|
USA | $24.77 Million |
|
KATORO GOLD PLC LS-01
F:622
|
Germany | €437.10K |
|
Osteopore Ltd
AU:OSX
|
Australia | AU$4.50 Million |
Liability Composition Analysis (2012–2025)
This chart breaks down Arcadia Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Arcadia Biosciences Inc.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.09 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.58 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.37 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Arcadia Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Arcadia Biosciences Inc (2012–2025)
The table below shows the annual total liabilities of Arcadia Biosciences Inc from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $2.41 Million | -67.01% |
| 2024-12-31 | $7.29 Million | +4.17% |
| 2023-12-31 | $7.00 Million | -12.72% |
| 2022-12-31 | $8.02 Million | -36.94% |
| 2021-12-31 | $12.72 Million | -32.32% |
| 2020-12-31 | $18.80 Million | -22.48% |
| 2019-12-31 | $24.25 Million | +116.33% |
| 2018-12-31 | $11.21 Million | +30.90% |
| 2017-12-31 | $8.56 Million | -75.09% |
| 2016-12-31 | $34.38 Million | +1.06% |
| 2015-12-31 | $34.02 Million | +27.05% |
| 2014-12-31 | $26.77 Million | -0.24% |
| 2013-12-31 | $26.84 Million | +40.94% |
| 2012-12-31 | $19.04 Million | -- |
About Arcadia Biosciences Inc
Arcadia Biosciences, Inc. produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief,… Read more